|
CYB5RL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.127298502965E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.69979627332395E-11 |
| Normal-vs-Stage2 |
3.06490000046011E-08 |
| Normal-vs-Stage3 |
2.34340324922755E-11 |
| Normal-vs-Stage4 |
9.12270259334491E-11 |
| Stage1-vs-Stage2 |
5.009600E-01 |
| Stage1-vs-Stage3 |
4.012000E-01 |
| Stage1-vs-Stage4 |
4.477000E-01 |
| Stage2-vs-Stage3 |
2.616800E-01 |
| Stage2-vs-Stage4 |
3.029400E-01 |
| Stage3-vs-Stage4 |
9.095400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.59979823727485E-11 |
| Normal-vs-AfricanAmerican |
6.47529999620033E-08 |
| Normal-vs-Asian |
8.99310004243148E-09 |
| Caucasian-vs-AfricanAmerican |
5.055400E-01 |
| Caucasian-vs-Asian |
3.480800E-01 |
| AfricanAmerican-vs-Asian |
9.687600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.09110506688148E-11 |
| Normal-vs-Female |
7.08230141199806E-11 |
| Male-vs-Female |
3.236600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.96279717110815E-11 |
| Normal-vs-Age(41-60Yrs) |
4.25880442023185E-11 |
| Normal-vs-Age(61-80Yrs) |
2.66579980312542E-10 |
| Normal-vs-Age(81-100Yrs) |
3.36300000003398E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.597400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.112200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.089800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.103000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.490400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.229200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.953600E-02 |
| Classical-VS-Follicular |
7.706800E-01 |
| Classical-VS-Other |
2.807800E-01 |
| Classical-VS-Normal |
1.17129972387886E-10 |
| Tall-VS-Follicular |
3.945600E-02 |
| Tall-VS-Other |
9.369000E-01 |
| Tall-VS-Normal |
4.27069490882559E-12 |
| Follicular-VS-Other |
3.301200E-01 |
| Follicular-VS-Normal |
1.19349996552387E-09 |
| Other-VS-Normal |
7.357200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.49629983350985E-10 |
| Normal-vs-N1 |
4.59260407481565E-11 |
| N0-vs-N1 |
2.134400E-01 |
|
|
